NVS — NOVARTIS AG
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1114448 ·
Last close
$159.13
Market Cap
$302.46B
52W High
$165.96
52W Low
$119.60
ADV30
2,021,721
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 15,029,000,000 | 11,421,000,000 | 1,843,000,000 | 1,202,000,000 | 117,149,000,000 | 8,870,000,000 | 79,585,000,000 |
| Jun 2026 | 14,951,000,000 | 11,241,000,000 | 4,750,000,000 | 3,264,000,000 | 122,033,000,000 | 7,616,000,000 | 80,087,000,000 |
| Mar 2026 | 13,524,000,000 | 10,065,000,000 | 4,235,000,000 | 3,156,000,000 | 118,532,000,000 | 6,877,000,000 | 79,605,000,000 |
| Dec 2025 | 13,860,000,000 | 10,249,000,000 | 3,616,000,000 | 2,409,000,000 | 110,949,000,000 | 11,435,000,000 | 64,400,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$17,325,000,000
Investing CF
$-18,691,000,000
Financing CF
$778,000,000
CapEx
$-3,324,000,000
Dividends Paid
$-11,553,000,000
Buybacks
$-6,252,000,000
EPS Diluted TTM
$5.24
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$39,239,000,000
Inventory
$6,104,000,000
Receivables
$9,963,000,000
ST Investments
$105,000,000
EBIT TTM
$14,220,000,000
Pretax Income TTM
$12,643,000,000
Interest Exp TTM
$1,577,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,692,998,144
EBITDA
$23,097,999,360
Free Cash Flow
$11,900,250,112
Enterprise Value
$302,502,051,840
Total Cash
$7,617,999,872
Total Debt
$49,014,001,664
Shares Out
1,900,714,840
Trailing EPS
$6.62
Book Value
$21.86
ROE
30.3%
ROA
10.2%
Div Yield
3.46%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 56,674,000,000 | 17,644,000,000 | 13,984,000,000 | 110,949,000,000 | 64,400,000,000 | 46,130,000,000 | 19,144,000,000 |
| Dec 2024 | 51,722,000,000 | 14,544,000,000 | 11,941,000,000 | 102,246,000,000 | 58,120,000,000 | 44,046,000,000 | 17,619,000,000 |
| Dec 2023 | 46,660,000,000 | 9,769,000,000 | 14,850,000,000 | 99,945,000,000 | 53,195,000,000 | 46,667,000,000 | 14,458,000,000 |
| Dec 2022 | 43,461,000,000 | 7,946,000,000 | 6,955,000,000 | 117,453,000,000 | 58,030,000,000 | 59,342,000,000 | 14,236,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.84
Max Pain — expiry 2026-12-18
max pain strike: $160.00 · spot: $155.21 · call oi: 7,832 · put oi: 14,956
Expected Move to 2026-12-18:
±$9.65
(6.22%) —
implied range
$145.56 –
$164.86
· ATM straddle on $155.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AZN | ASTRAZENECA PLC | $282.68B | $182.27 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| ABT | ABBOTT LABORATORIES | $181.35B | $104.71 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| PFE | PFIZER INC | $162.27B | $28.47 | — |
News headlines (Yahoo Finance, 1h cache)
Former Novartis U.S. Chief Strategy Officer Scott Howell, MD, MBA, Joins GOA Therapeutics as Chief Commercial Officer
2026-11-18 18:30 · Yahoo
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
2026-11-18 14:45 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS
2026-11-18 06:00 · Yahoo
Drug and Gene Delivery Devices - Global Strategic Business Report 2026: Capitalize on 8.1% CAGR to Secure the $1.2 Billion Market by 2032 as AbbVie, Moderna, Pfizer and Novartis Accelerate
2026-11-17 15:02 · Yahoo
FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
2026-11-17 14:24 · Yahoo
Novartis Receives FDA Approval for Cosentyx in Polymyalgia Rheumatica
2026-11-17 11:22 · Yahoo
How Investors Are Reacting To Novartis (SWX:NOVN) Drug Approval Progress
2026-11-16 21:17 · Yahoo
Novartis (SWX:NOVN), What Is Behind The Fresh Attention?
2026-11-16 20:23 · Yahoo
What Is Novartis (SWX:NOVN) Signaling With Its Latest Immunology Progress?
2026-11-16 19:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.